- Clinical Professor, Global Health
- Clinical Professor, Medicine - Allergy and Infectious Dis.
- Chief Executive Officer, Infectious Disease Research Institute
- Affiliate Professor, Vaccine and Infectious Disease Division, Fred Hutch
Select from the following:
Corey Casper is the Chief Executive Officer at the Infectious Disease Research Institute (IDRI). At IDRI, Dr. Casper oversees a portfolio of vaccines, therapeutics, and diagnostics that provide comprehensive solutions to global health problems. These include immune-enhancing adjuvant formulations that enable strong, safe and durable vaccines, a novel RNA vaccine platform for the prevention of pandemic / emerging viruses, and products for the treatment and prevention of cancer in low- and middle-income countries.
Dr. Casper's research focuses on the relationship between infectious diseases, immunity and cancer. He has authored >125 peer-reviewed publications, and has received funding as the Principal Investigator of >$100 million in NIH and industry-sponsored studies.
Dr. Casper also is the Associate Director of the Center for AIDS Research) and an Affiliate Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center (where he served as Associate Cancer Center Director and Founding Head of the Global Oncology Program). He sees patients with infectious diseases and cancer at the Seattle Cancer Care Alliance and the UW Medical Center.
- MD (Cornell University)
- MPH (University of Washington)
- Biodefense Infectious Diseases
- Cervical Cancer
- Clinical Mentoring
- Drug and Vaccine Development
- Host-Pathogen Interactions
- Infectious Diseases (other than STDs)
- Innate Immunity
- Laboratory Strengthening
- Neglected Diseases, Tropical Medicine (incl. Parasites)
- Non-Communicable Diseases
- Pulmonary Diseases and Pneumonia
- STDs (other than HIV)
- Biological Determinants of Natural History of AIDS-Defining Cancers
- Clinical Development of a Therapeutic Vaccine for Tuberculosis
- CYNK-001 for the Treatment of Moderate COVID-19
- Development and Evaluation of a Self-Amplifying and Self Adjuvanting SARS-CoV-2 RNA Vaccine
- HIV integration-mediated modulation of immune regulation in HPV-associated cancers
- Multivalent Flavivirus Vaccine Development Using a Flexible Replicating RNA Platform
Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis. 2008;198(1):23-30. doi: 10.1086/588820. PubMed PMID: 18491970; PMCID: PMC2700177.
Coghill AE, Newcomb PA, Madeleine MM, Richardson BA, Mutyaba I, Okuku F, Phipps W, Wabinga H, Orem J, Casper C. Contribution of HIV infection to mortality among cancer patients in Uganda. AIDS. 2013;27(18):2933-42. doi: 10.1097/01.aids.0000433236.55937.cb. PubMed PMID: 23921614; PMCID: PMC4319357.
van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. PubMed PMID: 25042199.
Gantt S, Orem J, Krantz EM, Morrow RA, Selke S, Huang ML, Schiffer JT, Jerome KR, Nakaganda A, Wald A, Corey L+, Casper C+ Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. J Infect Dis. 2016;214(1):36-44. doi: 10.1093/infdis/jiw076. PubMed PMID: 26917575; PMCID: PMC4907408.
Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019 Mar 21;133(12):1313-1324. doi: 10.1182/blood-2018-09-871418. Epub 2019 Jan 7. PubMed PMID: 30617194; PubMed Central PMCID: PMC6428665.
Denburg AE, Laher N, Mutyaba I, McGoldrick S, Kambugu J, Sessle E, Orem J, Casper C. The cost effectiveness of treating Burkitt lymphoma in Uganda. Cancer. 2019 Jun 1;125(11):1918-1928. doi: 10.1002/cncr.32006. Epub 2019 Mar 6. PubMed PMID: 30840316.
Gagliardi A, Porter VL, Zong Z, Bowlby R, Titmuss E, Namirembe C, Griner NB, Petrello H, Bowen J, Chan SK, Culibrk L, Darragh TM, Stoler MH, Wright TC, Gesuwan P, Dyer MA, Ma Y, Mungall KL, Jones SJM, Nakisige C, Novik K, Orem J, Origa M, Gastier-Foster JM, Yarchoan R, Casper C, Mills GB, Rader JS, Ojesina AI, Gerhard DS, Mungall AJ, Marra MA. Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. Nat Genet. 2020;52(8):800-10.